# Study of ONO-4538 in Gastric Cancer

> **NCT02746796** · PHASE2,PHASE3 · COMPLETED · sponsor: **Ono Pharmaceutical Co., Ltd.** · enrollment: 680 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** ONO-4538
- **DRUG:** Oxaliplatin
- **DRUG:** Tegafur- Gimeracil-Oteracil potassium
- **DRUG:** Capecitabine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02746796
- **Lead sponsor:** Ono Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2020-01
- **Final completion:** 2022-11-17
- **Target enrollment:** 680 (ESTIMATED)
- **Last updated:** 2024-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02746796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02746796, "Study of ONO-4538 in Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02746796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*